Recent changes to US tariff policies in the first half of 2025 have influenced the medical device sector, including the US hip reconstruction market. However, the reported data shows robust year-over-year growth in both Q1 and Q2 of 2025, highlighting a stable and positively trending market environment for medical device companies, says GlobalData.
Insights from GlobalData’s comprehensive dataset, encompassing reports from 2,600 medical facilities and representing approximately 18-20 per cent of US hospitals, suggest 19 per cent year-over-year growth for domestic medical device companies in June 2025. However, GlobalData anticipates some potential fluctuations as more medical facilities continue reporting for this period.
Separately, financial disclosures from prominent US-based companies align with these observations. Zimmer Biomet reported a 3.7 per cent change in its US hip reconstruction net sales for Q1 2025. In the same period, Stryker reported a 7.6 per cent change. Johnson & Johnson recorded steady market progress as well, with a 5.9 per cent increase in Q1 2025, further growing to 7.8 per cent in Q2 2025.
Thomas Fleming, Medical Analyst at GlobalData, comments, “These positive market indicators, reinforced by both industry-wide data from GlobalData and company-specific financial reports, suggest favorable conditions for US medical device manufacturers. The tariff policy adjustments appear to be prompting some manufacturers to reevaluate and strengthen their domestic market presence, potentially at the expense of international competitors.”
Fleming continues, “While domestic manufacturers may currently be stabilising in the US tariff environment, international companies could encounter increasing pressure, potentially leading to market share shifts. Continuous monitoring and analysis of incoming data will be essential to comprehensively assess the long-term impacts of these tariff changes on both domestic and international companies operating in the US hip reconstruction market.”
Fleming concludes, “Although current indicators from GlobalData’s panel of US facilities underscore stability and growth, expectations of variability persist as more medical facilities submit updated data. Consequently, continued analysis will be crucial to fully understand the longer-term implications of US tariff adjustments on both domestic and international participants within the hip reconstruction market.”